Abstract
Zusammenfassung. Immun-Checkpoint-Inhibitoren (ICI) werden zunehmend bei verschiedenen Tumorerkrankungen eingesetzt. Autoimmune Nebenwirkungen (irAE) wie Colitis, Hepatitis oder Hautreaktionen sind den meisten Ärztinnen und Ärzten bekannt, allerdings gibt es viele weitere, seltenere, u.a. neurologische Nebenwirkungen wie myasthene Syndrome, Myopathien sowie Myasthenie/Myopathie-Overlap-Syndrome mit potenziell lebensbedrohlichen Komplikationen. Eine genaue Diagnose hat weitreichende therapeutische Konsequenzen. Hier präsentieren wir den Fall eines Patienten unter einer Immun-Checkpoint-Inhibitor-Therapie, bei dem sich die Diagnosestellung aufgrund des Vorhandenseins von Overlap-Symptomen als herausfordernd darstellte, die korrekte Diagnose allerdings aufgrund der therapeutischen Konsequenzen wichtig war.
Abstract. Immune-checkpoint-inhibitors are increasingly used in various malignancies. Autoimmune side effects such as colitis, hepatitis or skin reactions are well known, on the other hand neurological autoimmune complications such as myasthenic syndromes, myopathies or overlap syndromes with potentially life-threatening complications are less common and not well understood. A precise diagnosis has far reaching therapeutic consequences. Here we present the case of a patient under immune checkpoint inhibitor therapy, in which the diagnosis, due to the presence of overlap symptoms, is shown to be challenging. However, it was crucial to find the correct diagnosis in order to choose the proper therapy.
Bibliografie
, Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020;21(9):3054.
, Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985–e994.
, Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12–23.
. Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. Nervenarzt. 2019;90(2):138–147.
. A review of serious adverse effects under treatment with checkpoint inhibitors: Curr Opin Oncol. 2017;29(2):136–144.
. Neurological complications of immune checkpoint inhibitors: what happens when you ’take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11: 175628641879986.
, Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 2017;73:1–8.
, Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. J Peripher Nerv Syst. Peripher Nerv Syst. 2019;24 Suppl 2:S74-S85. doi: 10.1111/jns.12339.
. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy – review of the literature and future outlook. J Clin Med.2019;8(11):1777.
, Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol. 2019; 19(1):184.
. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018;48(1):7–12.
. Neuromuscular complications of immune checkpoint inhibitors. Presse Médicale. 2018;47(11–12):e253–e259.
. Neurological toxicities associated with immune-checkpoint inhibitors: Curr Opin Neurol. 2017;30(6):659–668.
U.S. Department of Health and Human Services . Common Terminology Criteria for Adverse Events (CTCAE). 2017;147. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf; letzter Zugriff: 21.04.2021.
